Company Overview and News

20
EGLT / Egalet Corporation 8-K (Current Report)

2018-09-19 sec.gov - 16
UNITED STATES
EGLT

10
EGLT / Egalet Corporation SC TO-I/A

2018-09-19 sec.gov - 6
UNITED STATES
EGLT

51
Abuse-Deterrent Opioids: A Business Answer To The Opioid Abuse Crisis

2018-09-13 seekingalpha - 2
The recent effort at addressing opioid abuse has been focused on limiting the availability of the drugs to abusers by limiting the number of prescriptions written by healthcare providers.
WBA MCK KMPH DEPO ENL CVS WMT PTIE ABC EGLT JNJ NVS PFE DRRX ENDP

19
EGLT / Egalet Corporation 8-K (Current Report)

2018-09-11 sec.gov - 15
UNITED STATES<
EGLT

5
EGLT / Egalet Corporation SC TO-I/A

2018-08-10 sec.gov - 1
UNITED S
EGLT

5
EGLT / Egalet Corporation S-B

2018-08-09 sec.gov - 1
As filed with the Securities and Exchange Commission on August 9, 2018. Registration No. <
EGLT

4
EGLT / Egalet Corporation 10-Q (Quarterly Report)

2018-08-09 sec.gov
eglt_Current folio_10Q Table of Contents
EGLT

4
Egalet Ltd. (EGLT) CEO Bob Radie on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good morning, ladies and gentlemen, and welcome to the Egalet 2018 Second Quarter's Earnings Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] After management's remarks, there will be an opportunity to ask questions [Operator Instructions]. As a reminder, today's conference call is being recorded.
EGLT

4
EGLT / Egalet Corporation 8-K (Current Report)

2018-08-08 sec.gov
UNITED STATES
EGLT

4
EGLT / Egalet Corporation SC TO-I

2018-07-31 sec.gov
UNITED STATES
EGLT

14
EGLT / Egalet Corporation 8-K (Current Report)

2018-07-11 sec.gov - 10
UNITED STATES
EGLT

46
Acura Pharmaceuticals Announces First Quarter 2018 Financial Results

2018-06-29 globenewswire - 1
PALATINE, Ill., June 29, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC PINK:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three months ended March 31, 2018.
EGLT ACUR

49
Acura Pharmaceuticals Announces Fourth Quarter 2017 and Full Year 2017 Financial Results

2018-06-07 globenewswire - 2
PALATINE, Ill., June 07, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC PINK:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and twelve months ended December 31, 2017.
EGLT KMPH ACUR

EGLT : Egalet Corporation Stock Analysis and Research Report

2017-10-20 - Asif

Egalet Corporation is a fully integrated specialty pharmaceutical company developing, manufacturing and commercializing innovative treatments for pain and other conditions. Given the need for acute and chronic pain products and the issue of prescription abuse, the company focused on bringing non-narcotic and abuse-deterrent (“AD”) opioid formulations to patients and physicians. Egalet is currently marketing ARYMO® ER (morphine sulfate) extended-release (“ER”) tablets, for oral use CII (“ARYMO ER”), SPRIX® (ketorolac tromethamine) Nasal Spray (“SPRIX Nasal Spray”), and OXAYDO® (oxycodone HCI, USP) tablets for oral use only—CII (“OXAYDO”). ARYMO ER, an ER morphine product formulated with abuse-deterrent properties and approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, is its first product developed using its proprietary Guardian™ Technology. Egalet acquired, and...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 28226B104